AMPH vs VTRS vs ALVO Stock Comparison

Amphastar Pharmaceuticals, Viatris and Alvotech Prices as of Nov 13, 2026 Peers: Industry group
VTRS Viatris Inc
$20.82 +19.4% 1M +90.8% 1Y
Market cap
$23.74B
P/E
–
Revenue (TTM)
$14.73B
Div. yield
–
Generic Drugs Healthcare
7 wins
ALVO Alvotech
$4.19 -19.0% 1M -24.1% 1Y
Market cap
$1.28B
P/E
–
Revenue (TTM)
-$131.44M
Div. yield
–
Generic Drugs Healthcare
1 win

Head to Head

10 decided of 12

Viatris leads on 7 of the 12 questions below (Viatris 7, Amphastar Pharmaceuticals 2, Alvotech 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMPHVTRSALVOLeader
Larger companyMarket capitalisation $1.25B $23.74B $1.28B VTRS
Cheaper on earningsLower P/E, profitable companies only 12.6x -39.1x -41.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.8x 7.8x — VTRS
Faster revenue growthRevenue growth, trailing twelve months +3.1% +4.3% -137.5% VTRS
More profitableNet margin, trailing twelve months 13.3% -4.1% — AMPH
Better return on capitalReturn on invested capital 7.6% 0.0% 8.2% ALVO
Less leveragedLower net debt / EBITDA 7.5x 4.1x 4.6x VTRS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +11.4% +90.8% -24.1% VTRS
Better 5-year returnAnnualised price return, 5 years +6.6%/yr +8.1%/yr -15.8%/yr VTRS
Less volatileAnnualised volatility, 1 year 53.3% 30.9% 70.5% VTRS
Higher overall scoreMean of the five percentile scores vs peers 72/100 66/100 66/100 AMPH

Percentile Scorecard

AMPHVTRSALVO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMPHVTRSALVO
Valuation 98 #13 of 660 92 #51 of 660 94 #41 of 660
Growth 41 #366 of 619 51 #303 of 619 79 #132 of 619
Profitability 87 #78 of 595 83 #105 of 595 71 #172 of 595
Financial Health 35 #443 of 683 24 #520 of 683 22 #536 of 683
Shareholder Returns 98 #12 of 459 81 #86 of 459 –
Overall 72 66 66
  • AMPH ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ALVO ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMPHVTRSALVOSPY
1 month +12.6%+19.4%-19.0% -2.0%
3 months +40.5%+28.3%+3.5% -2.8%
6 months +74.1%+26.3%+26.6% +2.0%
Year to date +9.7%+67.2%-18.3% +10.6%
1 year +11.4%+90.8%-24.1% +12.2%
3 years -47.8%+125.8%-53.4% +68.1%
3 years, per year -19.5%+31.2%-22.5% +18.9%
5 years +37.9%+47.6%-57.7% +61.4%
5 years, per year +6.6%+8.1%-15.8% +10.1%
10 years +40.3%-45.1%— +248.5%
10 years, per year +3.4%-5.8%— +13.3%

Risk

MeasureAMPHVTRSALVOSPY
Volatility, 1Y 53.3%30.9%70.5% 13.6%
Downside volatility, 1Y 66.0%28.6%65.0% 13.9%
Beta vs S&P 500, 1Y 0.430.650.84 1.00
Return / volatility, 1Y 0.212.94-0.34 0.90
Max drawdown, 5Y -74.0%-52.9%-82.6% -25.4%
From 52-week high -0.1%-1.1%-31.9% -3.2%
52-week high $29.40$21.06$6.15 $779.14
52-week low $16.87$10.19$3.00 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMPHVTRSALVO
P/E now vs peer median 12.6xmedian 17.0x -39.3xmedian 17.0x -39.2xmedian 17.0x
P/S now vs peer median 1.7xmedian 8.4x 1.6xmedian 8.4x -9.9xmedian 8.4x
EV/EBITDA now vs peer median 32.2xmedian 14.6x 12.6xmedian 14.6x 9.5xmedian 14.6x
P/FCF now vs peer median 9.0xmedian 19.0x 11.3xmedian 19.0x -10.7xmedian 19.0x
P/B now vs peer median 1.5xmedian 2.0x 1.7xmedian 2.0x -4.6xmedian 2.0x
PEG now vs peer median -4.05median 0.43 1.19median 0.43 —median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMPHVTRSALVO
Revenue $745.79M $14.73B -$131.44M
Gross profit $349.09M $5.20B -$270.71M
Operating income $139.74M -$4.60M $142.52M
Net income $98.96M -$607.80M $52.16M
Free cash flow $139.02M $2.11B -$122.64M
R&D $92.29M $1.00B $92.89M
EPS (diluted) $2.28 $-0.53 $-0.11
Cash & equivalents $204.59M $1.79B $172.36M
Total debt $613.00M $13.32B $1.40B
Shares (diluted) 43.38M 1.15B 291.34M
Enterprise value $150.34M $16.90B $730.70M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMPHVTRSALVO
P/E 12.6x -39.3x -39.2x
P/FCF 9.0x 11.3x -10.7x
P/Operating cash flow 7.1x 9.6x -22.5x
P/S 1.7x 1.6x -9.9x
P/B 1.5x 1.7x -4.6x
P/Tangible book 1.6x 39.4x -2.8x
EV/EBITDA 32.2x 12.6x 9.5x
EV/EBIT 11.7x -7,679x 17.8x
EV/Revenue 2.2x 2.4x -19.3x
EV/FCF 11.8x 16.7x -20.6x
EV/Operating cash flow 9.3x 14.2x -43.5x
PEG (3Y EPS CAGR) -4.05 1.19 –

Growth

14 metrics
MetricAMPHVTRSALVO
Revenue growth (1Y) 3.1% 4.3% -137.5%
Revenue CAGR (3Y) 7.4% -1.6% –
Gross profit growth (1Y) -2.2% 2.3% -383.2%
Gross profit CAGR (3Y) 2.3% -5.3% –
Operating income growth (1Y) -6.8% 99.8% 166.0%
Operating income CAGR (3Y) -8.2% -26.1% –
Net income growth (1Y) -11.3% 83.5% 122.5%
Net income CAGR (3Y) -9.9% -32.6% –
EPS growth (1Y) -2.6% 83.3% 87.7%
EPS CAGR (3Y) -3.1% -32.9% –
Operating cash flow growth (1Y) 15.1% 25.3% 75.4%
Operating cash flow CAGR (3Y) 0.1% -0.5% –
Free cash flow growth (1Y) 22.7% 27.1% 52.6%
Free cash flow CAGR (3Y) -0.2% -0.7% –

Profitability

14 metrics
MetricAMPHVTRSALVO
Gross margin 46.8% 35.3% –
EBITDA margin 6.8% 19.1% –
Operating margin 18.7% 0.0% –
Pretax margin 17.4% -3.6% –
Net margin 13.3% -4.1% –
FCF margin 18.6% 14.3% –
Operating cash flow margin 23.5% 16.9% 44.3%
Return on equity 12.5% -4.3% –
Return on assets 5.7% -1.7% -1.9%
Return on invested capital 7.6% 0.0% 8.2%
Return on capital employed 9.0% 0.0% 11.0%
Asset turnover 0.4x 0.4x -0.1x
Cash conversion (OCF / net income) 1.8x -4.1x -1.1x
Stock comp / revenue 4.0% 1.2% -5.0%

Financial Health

11 metrics
MetricAMPHVTRSALVO
Debt / assets 35.8% 38.4% 86.4%
Debt / equity 0.8x 1.0x -4.9x
Net debt / EBITDA 7.5x 4.1x 4.6x
Debt / FCF 4.4x 6.3x -11.4x
Liabilities / assets 52.4% 60.5% 117.6%
Equity / assets 47.6% 39.5% -17.6%
Interest coverage 5.3x 0.0x 44.7x
Current ratio 3.3x 1.6x 1.9x
Quick ratio 2.3x 0.8x 1.4x
Cash ratio 1.3x 0.3x 0.6x
Altman Z-score 2.44 1.21 -1.39

Shareholder Returns

7 metrics
MetricAMPHVTRSALVO
Dividend yield – 2.3% –
Net buyback yield 7.2% 1.6% –
Shareholder yield 7.2% 3.9% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMPHVTRSALVO
Forward P/E 8.8xFY2026 7.8xFY2026 –
EPS, next fiscal year $3.34FY2026 $2.66FY2026 $-0.04FY2026
EPS growth, next FY +2.8%FY2026 +13.2%FY2026 –
EPS growth, the year after +6.9% -1.9% –
Revenue, next fiscal year $802.03MFY2026 $15.33BFY2026 $555.88MFY2026
Revenue growth, next FY +11.4%FY2026 +7.2%FY2026 -6.3%FY2026
Revenue growth, the year after -5.7% -4.2% +23.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMPHVTRSALVO
Held by institutions 64.8% 89.9% 14.7%
Institutions holding 209 1,033 72
Change in shares held, QoQ -11.7% +5.6% +152.4%
Institutions buying 96 491 44
Institutions selling 74 318 17
Buyers to sellers 1.30 1.54 2.59

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMPHVTRSALVO
AMPH 1.00 0.35 0.14
VTRS 0.35 1.00 0.12
ALVO 0.14 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMPH, VTRS and ALVO?

Viatris (VTRS) is the largest by market capitalisation: Amphastar Pharmaceuticals (AMPH) $1.25B, Viatris (VTRS) $23.74B, Alvotech (ALVO) $1.28B.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Amphastar Pharmaceuticals (AMPH) +3.1%, Viatris (VTRS) +4.3%, Alvotech (ALVO) -137.5%.

Which company is more profitable?

Amphastar Pharmaceuticals (AMPH) has the highest net margin (Amphastar Pharmaceuticals (AMPH) 13.3%, Viatris (VTRS) -4.1%). On return on invested capital, Alvotech (ALVO) leads (Amphastar Pharmaceuticals (AMPH) 7.6%, Viatris (VTRS) 0.0%, Alvotech (ALVO) 8.2%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Amphastar Pharmaceuticals (AMPH) +11.4%, Viatris (VTRS) +90.8%, Alvotech (ALVO) -24.1%. Over five years, Viatris (VTRS) compounded fastest (Amphastar Pharmaceuticals (AMPH) +6.6%/yr, Viatris (VTRS) +8.1%/yr, Alvotech (ALVO) -15.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Amphastar Pharmaceuticals (AMPH) 53.3%, Viatris (VTRS) 30.9%, Alvotech (ALVO) 70.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMPH, VTRS and ALVO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.